Arnold Ventures Profile picture
Sep 24, 2019 3 tweets 4 min read Read on X
We are thrilled to announce the selection of 10 jurisdictions for the #ReducingRevocationsChallenge initiative w/@CUNYISLG, which aims to increase probation success through research & policy development. Congratulations to all finalists! arnoldventures.org/stories/arnold… @VinSchiraldi Image
@CUNYISLG @VinSchiraldi Probation revocations are a significant driver of #massincarceration, responsible for almost half of state prison admissions nationwide, and need urgent reform. #ReducingRevocationsChallenge arnoldventures.org/stories/arnold… @VinSchiraldi @CUNYISLG
@CUNYISLG @VinSchiraldi See the full list of jurisdictions who will receive $$ to find policy and practice solutions to probation revocations as part of the #ReducingRevocationsChallenge! arnoldventures.org/newsroom/arnol… @VinSchiraldi @CUNYISLG

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Arnold Ventures

Arnold Ventures Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @Arnold_Ventures

Jun 1, 2021
44% of people sentenced to jail have a diagnosed mental illness
63% have a substance use disorder
45% suffer from chronic health problems

Jail often makes these conditions worse.

So how should cities respond to people in crisis? With data-driven justice. 1/
Today @Arnold_Ventures released the final reports from a multiyear pilot site test of using coordination and data to divert people in crisis away from jails and toward the services they need, such as healthcare or housing. 2/
These documents are three years in the making. Each site released its own final report that delves into how they used power of data to understand and better address the needs of frequent utilizers. 3/
Read 10 tweets
Oct 8, 2020
As the nation grapples with unemployment & state budgets shrink amid #COVID-19, Nevada has a model that policy officials could implement and test to reemploy dislocated workers: It’s helping millions find jobs faster AND saving state money. arnoldventures.org/stories/nevada… #VPDebates
#COVID19 is also exacerbating our nation's retirement crisis in a very different way than the Great Recession: washingtonpost.com/business/2020/… #VPDebate
The case of #BreonnaTaylor is evidence that America’s social contract is in tatters. @sdpjohnson explains our current reckoning: arnoldventures.org/stories/to-our… #VPDebate
Read 13 tweets
Oct 1, 2020
“I’m so grateful for #Gleevec. It keeps me alive. But the price tag ($10k/month) constantly hangs over my head.”
"When I'm on Enbrel, I don't have symptoms... But I also have to carry the fear knowing all this could be ripped away." Enbrel is priced at $6k per month.
First up: autoimmune drug Enbrel. Even though the primary patent on Enbrel expired in 2010, $AMGN has filed more than 50 additional patents on the drug to thwart cheaper competition, according to analysis by @IMAKglobal (1/) statnews.com/2020/09/29/dru…
Read 45 tweets
Sep 30, 2020
Medicare spent hundreds of millions of $$$ more on Copaxone each year because of its inability to negotiate directly @46brooklyn @akesselheim
Even Teva’s own employees could not afford Copaxone at its price. One said she could no longer afford Copaxone because she would have to pay $1,673.33 out of pocket as compared to $12 for Mylan’s generic product.
After Mylan introduced a lower-priced generic version of Copaxone 40 mg/ml in October 2017, Teva implemented several new exclusionary tactics to limit generic competition and maintain profits.
Read 4 tweets
Sep 30, 2020
First up: #Revlimid, a drug that costs $20k for a 28-day supply. The Committee reviewed more than 50k pages of internal communications & data from 2009 to now. Since Revlimid launched in '05, Celgene raised the price 22 times (1/) oversight.house.gov/sites/democrat…
After Bristol Myers Squibb obtained the rights to Revlimid last November, it raised the price again to $763/pill. The price has tripled in 15 years (2/)
Revlimid is a textbook case of profits over patients (3/)
Read 8 tweets
Sep 24, 2020
Pres. Trump, touting his record on drug prices, pledges to issue $200 cards to all seniors. Reality check 👇
1) The legal authority to issue these cards is questionable, at best.
2) Pres. Trump's recently issued executive orders will do nothing to lower drug prices immediately.
Read 4 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

:(